Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
PEGANONE (ethotoin) is an oral aromatic antiepileptic drug approved in 1957 for the management of generalized tonic-clonic and complex partial seizures. It is a hydantoin derivative that stabilizes neuronal membranes and raises seizure threshold. This legacy agent represents an older generation of anticonvulsants now rarely used in modern epilepsy management.
This legacy product approaches loss of exclusivity with minimal commercial investment; career opportunities are limited to small maintenance teams focused on compliance and existing patient retention rather than growth.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career professionals seeking substantive roles in drug development, commercialization, or innovation should avoid this product; opportunities are confined to small regulatory, compliance, and operational teams managing a mature, declining asset. Working on PEGANONE offers limited career growth trajectory and visibility within modern pharmaceutical organizations.
Worked on PEGANONE at Recordati? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.